Perrild H, Jessen-Jürgensen H, Pedersen F, Fogh-Andersen N
Department of Internal Medicine, Herlev Hospital, Denmark.
Eur J Clin Pharmacol. 1988;34(3):299-301. doi: 10.1007/BF00540959.
In 40 patients with ischaemic heart disease the serum levels of magnesium, parathyroid hormone (PTH), phosphate, calcium, and ionized calcium remained unchanged and within normal limits following treatment for 12 months with alprenolol (n = 20) or placebo (n = 20). No changes occurred during a 2 week withdrawal period. The clinical implication is that the non-cardioselective betablocker alprenolol can be given to patients with ischaemic heart disease without the risk of inducing potentially cardiotoxic disturbances in serum magnesium and serum calcium levels. Whether this applies to cardioselective beta-blockers remains to be established.
在40例缺血性心脏病患者中,20例接受阿普洛尔治疗、20例接受安慰剂治疗,治疗12个月后,血清镁、甲状旁腺激素(PTH)、磷酸盐、钙和离子钙水平保持不变且在正常范围内。在2周的撤药期内未发生变化。临床意义在于,非心脏选择性β受体阻滞剂阿普洛尔可用于缺血性心脏病患者,而不会有引起血清镁和血清钙水平潜在心脏毒性紊乱的风险。这是否适用于心脏选择性β受体阻滞剂仍有待确定。